-
-
-
-
-
-
-
Travere Therapeutics (TVTX) Reiterated at Hold by Stifel After FDA Asks for More Info
-
-
-
-
-
-
-
Jefferies on Travere Therapeutics (TVTX): 'AdCom Cancellation Clear Positive In Our View Setting Stage For Likely Approval'
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) PT Lowered to $20 at Stifel
-
-
-
-
-
-
-
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
-
-
-
-
-
-
-
Travere Therapeutics Provides Corporate Update and 2025 Outlook
-
-
-
-
-
-
-
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
Travere Therapeutics Reports Third Quarter 2022 Financial Results
-
15,430 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

